专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

EP2833905B1 COMBINATION THERAPY WITH HYALURONIDASE AND A TUMOR-TARGETED TAXANE 有权
标题翻译：与透明质酸酶和肿瘤靶向紫杉烷的组合治疗
公开(公告)号：EP2833905B1
公开(公告)日：2018-05-02
申请号：EP13715069.4
申请日：2013-03-15
申请人： Halozyme, Inc.
发明人： MANEVAL, Daniel, C. , SHEPARD, H., Michael , THOMPSON, Curtis, B.
IPC分类号： A61K38/47 , A61K9/00 , A61K9/107 , A61K9/127 , A61K9/50 , A61K9/51 , A61K31/337 , A61K31/37 , A61K31/42 , A61K31/573 , A61K31/706 , A61K31/7068 , A61K31/7076 , A61K31/7088 , A61K45/06 , A61K47/56 , A61K47/60 , A61K47/64 , A61P35/00 , C12N9/06 , C12N9/26
CPC分类号： A61K31/337 , A61K9/0019 , A61K31/37 , A61K31/42 , A61K31/56 , A61K31/573 , A61K31/706 , A61K31/7068 , A61K31/7076 , A61K31/7088 , A61K38/47 , A61K45/06 , A61K47/56 , A61K47/60 , A61K47/643 , C12N9/003 , C12N9/2474 , C12Y105/01003 , C12Y302/01035 , A61K2300/00
摘要： Provided herein is combination therapy containing an anti-hyaluronan agent, such as a polymer-conjugated hyaluronan-degrading enzyme, and a tumor-targeted taxane, and optionally a further chemotherapeutic agent such as a nucleoside analog. The combination therapy can be used in methods of treating cancers, and in particular solid tumor cancers.

2. 发明授权

EP2797622B1 PH20 POLYPEPTIDE VARIANTS, FORMULATIONS AND USES THEREOF 有权
标题翻译： PH20多肽制剂和它们的用途
公开(公告)号：EP2797622B1
公开(公告)日：2016-10-12
申请号：EP12816624.6
申请日：2012-12-28
申请人： Halozyme, Inc.
发明人： WEI, Ge , SHEPARD, H., Michael , ZHAO, Qiping , CONNOR, Robert, James
IPC分类号： A61K38/47 , A61K31/337 , C12N9/26 , A61K38/43
CPC分类号： C12N9/2474 , A61K9/0019 , A61K38/00 , A61K38/28 , A61K38/47 , A61K45/06 , A61K47/10 , C12Q1/34 , C12Y302/01035 , G01N2333/926 , G01N2333/928 , Y02A50/463 , A61K2300/00
摘要： Modified PH20 hyaluronidase polypeptides, including modified polypeptides that exhibit increased stability and/or increased activity, are provided. Also provided are compositions and formulations and uses thereof.

3. 发明公开

EP2818543A4 BACILLUS, HYALURONIC ACID ENZYME, AND USES THEREOF 有权转让
标题翻译：芽孢杆菌，透明质酸酶及其用途
公开(公告)号：EP2818543A4
公开(公告)日：2015-11-04
申请号：EP12869142
申请日：2012-11-29
申请人： BLOOMAGE FREDA BIOPHARM CO LTD
发明人： GUO XUEPING , SHI YANLI , QIAO LIPING , FENG NING , WANG GUANFENG , LI HAINA , XUE WEI , WANG HAIYING , LUAN YIHONG , LIU AIHUA
IPC分类号： C12N1/20 , A61K8/73 , A61K31/728 , A61P9/00 , A61P17/02 , A61Q17/00 , C07K14/32 , C12N9/26 , C12N15/56 , C12P19/28 , C12R1/07
CPC分类号： C12N9/2474 , A23L33/17 , A23V2002/00 , A61K8/66 , A61K8/735 , A61K31/728 , A61Q17/04 , A61Q19/00 , A61Q19/004 , A61Q19/02 , A61Q19/08 , C08B37/0072 , C12N9/2408 , C12P19/26 , C12P19/28 , C12R1/07 , Y02P20/52
摘要： The present invention provides a bacillus sp. having a deposit access number of CGMCC NO. 5744 and a hyaluronidase produced by the bacillus and the amino acid sequence of the hyaluronidase is shown in SEQ ID NO: 2. The present invention further relates to a process for preparing oligomeric hyaluronic acid or salts thereof or low-molecular-weight hyaluronic acid or salts thereof by using the bacillus or the hyaluronidase produced thereby. The produced oligomeric hyaluronates or low-molecular-weight hyaluronates have advantages such as good transdermal absorption ability, high purity, no cytotoxicity, potent antioxidant ability. The present invention also provides use of the bacillus having a deposit access number of CGMCC NO. 5744, or the hyaluronidase, oligomeric hyaluronates or salts thereof, low-molecular-weight hyaluronates or salts thereof produced by the bacillus in the fields of osmetics, food products and medicines.

4. 发明授权

EP2163643B1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof 有权转让
标题翻译：可溶性Hyaluronidaseglykoprotein（sHASEGP的），处理用于其生产，使用和药物组合物包含本
公开(公告)号：EP2163643B1
公开(公告)日：2015-01-21
申请号：EP09012670.7
申请日：2004-03-05
申请人： Halozyme, Inc.
发明人： Bookbinder, Louis, H. , Kindu, Anirban , Frost, Gregory, L.
IPC分类号： C12N9/26
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： The invention relates to the discovery of novel soluble active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified aminoterminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optical activity.
摘要翻译：本发明涉及新的可溶性透明质酸酶的活性糖蛋白（的sHASEGP），制造方法，及其使用促进其他分子的施用或减轻糖胺聚糖有关的病状的发现。最低限度地可溶，中性活性的sHASEGP结构域的活性的多肽结构域被描述并包括用于功能中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。包括的是改性氨基末端引导肽也提高的sHASEGP分泌。唾液酸化本发明还包括和重组的sHASEGP的聚乙二醇化形式超过天然存在的屠宰场酶增强稳定性和血清药代动力学。进一步描述的是从真核细胞衍生的基本上纯化的重组的sHASEGP糖蛋白的合适的式灰确实产生用于其光学活性所需的适当的糖基化。

5. 发明公开

EP2594274A4 NOVEL HYALURONIC ACID DECOMPOSITION-PROMOTING FACTOR AND INHIBITOR THEREOF 有权转让
标题翻译：新的因素，促进透明质酸及抑制剂的恶化THEREOF
公开(公告)号：EP2594274A4
公开(公告)日：2013-11-20
申请号：EP11789484
申请日：2011-06-03
申请人： KAO CORP
发明人： YOSHIDA HIROYUKI , INOUE SHINTARO , SAKAI SHINGO , NAGAOKA AYA
IPC分类号： A61K31/7088 , A61K8/40 , A61K8/42 , A61K8/49 , A61K8/73 , A61K31/365 , A61K31/4015 , A61K31/5415 , A61K31/713 , A61K38/00 , A61K39/395 , A61K45/00 , A61K48/00 , A61P17/02 , A61P17/16 , A61P19/02 , A61P27/16 , A61P35/00 , A61P43/00 , A61Q19/00
CPC分类号： C07K16/40 , A61K8/42 , A61K8/44 , A61K8/49 , A61K8/4913 , A61K8/498 , A61K8/602 , A61K8/606 , A61K8/64 , A61K8/735 , A61K9/0014 , A61K31/16 , A61K31/198 , A61K31/35 , A61K31/365 , A61K31/40 , A61K31/4015 , A61K31/5415 , A61K31/7048 , A61K31/7088 , A61K31/713 , A61K31/728 , A61K38/00 , A61K39/3955 , A61K48/005 , A61K2800/782 , A61Q19/007 , A61Q19/08 , C07K7/08 , C07K14/47 , C07K16/18 , C07K2317/34 , C12N9/2474 , C12N15/113 , C12N15/1137 , C12N15/52 , C12N2310/11 , C12N2310/111 , C12N2310/14 , C12N2320/32 , C12Q1/025 , G01N33/5023 , G01N2400/40 , G01N2500/10
摘要： The present invention is directed to KIAA1199, which is a novel factor involved in decomposition of hyaluronic acid, and to use thereof. More specifically, the invention is directed to a hyaluronic acid decomposition-promoting agent containing the KIAA1199 gene and a protein encoded by the gene; to a hyaluronic acid decomposition-inhibiting agent characterized by inhibiting the activity or expression thereof (including an siRNA or a monoclonal antibody); and to a method for screening a novel hyaluronic acid decomposition-controlling agent, in which the method contains employing the expression of KIAA1199 as an index.
摘要翻译：本发明涉及KIAA1199，所有这是在透明质酸的分解所涉及的新的因子，以及其用途。更具体地，本发明涉及到含有KIAA1199基因和由该基因编码的蛋白质的透明质酸分解促进剂; 到透明质酸分解抑制剂，其特征在于抑制活性或表达它们（包括siRNA或单克隆抗体的）; 并用于筛选新颖的透明质酸分解控制剂，其中该方法包含用人KIAA1199表达作为指标的方法。

6. 发明公开

EP2405015A3 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof 有权转让
标题翻译：可溶性Hyaluronidaseglykoprotein（sHASEGP的），因为其生产过程，用途和药物Zusammensetzunge包含该
公开(公告)号：EP2405015A3
公开(公告)日：2012-03-07
申请号：EP10183410.9
申请日：2004-03-05
申请人： Halozyme, Inc.
发明人： Bookbinder, Louis , Kundu, Anirban , Frost, Gregory
IPC分类号： C12P21/06 , C12N9/00 , C12N9/24 , C12N1/20 , C12N15/00 , C07H21/04 , C12N9/26 , C07K14/435
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linlced sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
摘要翻译：本发明涉及新的可溶性透明质酸酶的活性糖蛋白（的sHASEGP），制造方法，及其使用促进其他分子的施用或减轻糖胺聚糖有关的病状的发现。最低限度地可溶，中性活性的sHASEGP结构域的活性的多肽结构域被描述并包括用于功能中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。包括的是改性氨基末端引导肽也提高的sHASEGP分泌。唾液酸化本发明还包括和重组的sHASEGP的聚乙二醇化形式超过天然存在的屠宰场酶增强稳定性和血清药代动力学。进一步描述的是从真核细胞衍生的基本上纯化的重组的sHASEGP糖蛋白的合适的式灰确实产生用于其光学活性所需的适当的糖基化。

7. 发明公开

EP2330213A1 Soluble hyaluronidase glycoprotein (sHASEGP), process for preparing the same, uses and pharmaceutical compositions comprising thereof 审中-公开
标题翻译：可溶性Hyaluronidaseglykoprotein（sHASEGP的），因为其生产过程，用途和药物Zusammensetzunge包含该
公开(公告)号：EP2330213A1
公开(公告)日：2011-06-08
申请号：EP10183285.5
申请日：2004-03-05
申请人： Halozyme, Inc.
发明人： Bookbinder, Louis , Kundu, Anirban , Frost, Gregory
IPC分类号： C12P21/06 , C12N9/00 , C12N9/24 , C12N1/20 , C12N15/00 , C07H21/04
CPC分类号： A61K38/47 , A61K9/0048 , A61K38/00 , A61K39/395 , A61K47/48215 , A61K2039/505 , C12N9/2474 , C12Y302/01035 , Y02A50/475
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGP's), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occurring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.
摘要翻译：本发明涉及新的可溶性中性活性透明质酸酶的糖蛋白的发现（的sHASEGP的），制造，和它们的使用方法，以促进其它分子的施用或减轻的糖胺聚糖相关的病理学。最低限度地可溶，中性活性的sHASEGP结构域的活性的多肽结构域被描述并包括用于功能中性活性透明质酸酶结构域所需的天冬酰胺连接的糖部分。包括的是改性氨基末端引导肽也提高的sHASEGP分泌。唾液酸化本发明还包括和重组的sHASEGP的聚乙二醇化形式超过天然存在的屠宰场酶增强稳定性和血清药代动力学。进一步描述的是从真核细胞衍生的基本上纯化的重组的sHASEGP糖蛋白的合适的式灰确实产生用于其最佳活性所需的适当的糖基化。

8. 发明公开

EP1858926A4 SOLUBLE GLYCOSAMINOGLYCANASES AND METHODS OF PREPARING AND USING SOLUBLE GLYCOSAMINOGLYCANASES 有权转让
标题翻译：易溶GLYKOSAMINOGLYKANASEN和方法进行生产和使用即时GLYKOSAMINOGLYKANASEN
公开(公告)号：EP1858926A4
公开(公告)日：2011-05-11
申请号：EP06736105
申请日：2006-02-23
申请人： HALOZYME INC
发明人： BOOKBINDER LOUIS H , KUNDU ANIRBAN , FROST GREGORY I , HALLER MICHAEL F , KELLER GILBERT A , DYLAN TYLER M
IPC分类号： C07K16/00 , A01K67/027 , A01K67/033 , A01N37/18 , A01N43/04 , A61K38/17 , A61K38/47 , C07H21/02 , C07H21/04 , C07K1/00 , C12N5/00 , C12N9/24 , C12N15/00 , C12P21/06
CPC分类号： A61K47/48215 , A61K35/768 , A61K38/465 , A61K38/47 , A61K39/395 , A61K39/3955 , A61K47/60 , A61K2039/505 , C12N7/00 , C12N9/2408 , C12N9/2474 , A61K2300/00
摘要： The invention relates to the discovery of novel soluble neutral active Hyaluronidase Glycoproteins (sHASEGPs), methods of manufacture, and their use to facilitate administration of other molecules or to alleviate glycosaminoglycan associated pathologies. Minimally active polypeptide domains of the soluble, neutral active sHASEGP domains are described that include asparagine-linked sugar moieties required for a functional neutral active hyaluronidase domain. Included are modified amino-terminal leader peptides that enhance secretion of sHASEGP. The invention further comprises sialated and pegylated forms of a recombinant sHASEGP to enhance stability and serum pharmacokinetics over naturally occuring slaughterhouse enzymes. Further described are suitable formulations of a substantially purified recombinant sHASEGP glycoprotein derived from a eukaryotic cell that generate the proper glycosylation required for its optimal activity.

9. 发明公开

EP1624057A3 Verfahren zur Herstellung eines eine Hyaluronidase enthaltenden Präparates 无效
标题翻译：一种含有透明质酸酶的准备处理
公开(公告)号：EP1624057A3
公开(公告)日：2007-03-07
申请号：EP05090293.1
申请日：1998-06-15
申请人： Riemser Arzneimittel AG
发明人： von Below, Gudrun , Schweigle, Bernhard , Göricke, Bernd
IPC分类号： C12N9/26 , C07K14/435 , A61K38/47 , A61K35/48 , A61P35/00 , A61P37/02
CPC分类号： A61K35/48 , A61K38/47 , C12N9/2474 , C12Y302/01035
摘要： Die Erfindung betrifft ein Verfahren zur Herstellung eines eine Hyaluronidase ent- haltenden Präparats, wobei Stierhoden zu einem Brei zekleinert werden, wobei aus dem Brei Proteine und Enzyme im Sauren ein Eluat bildend gelöst werden, wobei das Eluat einer fraktionierten Ammoniumsulfatfällung unterworfen und so eine Hyaluronidasefällungsfraktion erhalten wird, wobei die Hyaluronidasefällungsfraktion einer Dialyse zur Abtrennung von Ammoniumsulfat unterworfen wird, wobei die dialysierte Hyaluronidasefällungsfraktion zur Aufreinigung einer Adsorption und Desorptionsverfahrenstufe an Aluminiumoxidhydrat unterworfen wird und wobei die aufgereinigte Hyaluronidasefällungsfraktion galenisch hergerichtet wird. Die Erfindung ist dadurch gekennzeichnet, daß die fraktionierte Ammoniumsulfatfällung in einer ersten Fällungsstufe in einer 10-29 Gew.-%igen wäßrigen Ammoniumsulfatlösung und in einer zweiten Fällungsstufe in einer 15-65 Gew.-%igen wäßrigen Ammoniumsulfatlösung durchgeführt wird und daß die aufgereinigte Hyaluronidasefällungsfraktion vor der galenischen Herrichtung einer Ultrafiltration mit einer Ausschlußgrenze von 5.000 bis 30.000 Dalton unterzogen wird.

10. 发明公开

EP1670917A1 SYNTHETIC HEPARANASE MOLECULES AND USES THEREOF 审中-公开
标题翻译：合成及其用途HEPARANASEMOLEKÜLE
公开(公告)号：EP1670917A1
公开(公告)日：2006-06-21
申请号：EP04765405.8
申请日：2004-09-17
申请人： ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI S.P.A.
发明人： LAHM, Armin, IRBM , NARDELLA, Caterina, IRBM , PALLAORO, Michele, IRBM , STEINKUHLER, Christian, IRBM
IPC分类号： C12N15/56 , C12N15/62 , C12N15/866 , C12N9/24 , C12N5/10
CPC分类号： C12Y302/01166 , C12N9/2402 , C12N9/2474 , C12Y302/01035
摘要： The present invention relates to synthetically produced, enzymatically active heparanase nucleic acid molecules that are capable of expression in high yield heterologous expression systems, and to polypeptides encoded by said molecules. Also provided herein are methods of expressing mammalian heparanase in heterologous expression systems, wherein high yields of biologically active heparanase are produced compared to prior art methods.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式